Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

 

 Permissions and Reprints

Abstract

Patients with intermediate-risk pulmonary embolism (PE) may, depending on the method and cut-off values used for definition, account for up to 60% of all patients with PE and have an 8% or higher risk of short-term adverse outcome. Although four non-vitamin K-dependent direct oral anticoagulants (NOACs) have been approved for the treatment of venous thromboembolism, their safety and efficacy as well as the optimal anticoagulation regimen using these drugs have not been systematically investigated in intermediate-risk PE. Moreover, it remains unknown how many patients with intermediate-high-risk and intermediate-low-risk PE were included in most of the phase III NOAC trials. The ongoing Pulmonary Embolism International Thrombolysis 2 (PEITHO-2) study is a prospective, multicentre, multinational, single-arm trial investigating whether treatment of acute intermediate-risk PE with parenteral heparin anticoagulation over the first 72 hours, followed by the direct oral thrombin inhibitor dabigatran over 6 months, is effective and safe. The primary efficacy outcome is recurrent symptomatic venous thromboembolism or death related to PE within the first 6 months. The primary safety outcome is major bleeding as defined by the International Society on Thrombosis and Haemostasis. Secondary outcomes include all-cause mortality, the overall duration of hospital stay (index event and repeated hospitalizations) and the temporal pattern of recovery of right ventricular function over the 6-month follow-up period. By applying and evaluating a contemporary risk-tailored treatment strategy for acute PE, PEITHO-2 will implement the recommendations of current guidelines and contribute to their further evolution.

Authors' Disclosures

Frederikus Klok reports research grants from Bayer, research grants from Bristol-Myers Squibb, research grants from Boehringer Ingelheim and non-financial research support from Daiichi Sankyo. Stefano Barco has received congress and travel payments from Daiichi Sankyo and Bayer HealthCare and financial support for the printing costs of his PhD thesis from Pfizer bv, CSL Behring bv, Sanquin Plasma Products, Boehringer Ingelheim bv, Aspen Netherlands and Bayer bv. Benjamin Brenner declares receiving honoraria for lectures and advisory board contributions from Pfizer, LEO Pharma, Sanofi and ROVI Laboratories. Matthias Held reports grants from Actelion, honoraria for lectures from Actelion, Bayer HealthCare, Berlin-Chemie, Boehringer Ingelheim, GSK, Novartis, Pfizer, honoraria for advisory board activities from Actelion, Bayer HealthCare, GSK, MSD and participation in clinical trials of Actelion, Bayer HealthCare, GSK, Pfizer, United Therapeutics, outside the submitted work. Daniel Duerschmied has received lecture honoraria from Bayer HealthCare and Pfizer and payment for travel accommodation/meeting expenses from Bayer HealthCare and Orion Pharma. Menno V. Huisman received research grants as well as fees for speaking and consulting from Boehringer Ingelheim, Bayer HealthCare, BMS-Pfizer, Daiichi Sankyo, MSD and Aspen. Guy Meyer reports travel support from Leo Pharma, BMS-Pfizer, Stago and Bayer HaelthCare and institutional grants from Leo Pharma, Bayer HaelthCare and BMS-Pfizer. Antoniu Petriş reports having received consultancy and lecture honoraria from Bayer HealthCare, Boehringer Ingelheim, Servier Pharma, AstraZeneca Pharma and BMS-Pfizer and payment for travel accommodation/meeting expenses from Bayer HealthCare and Boehringer Ingelheim. Franck Verschuren reports research support from Boehringer Ingelheim, Portola Pharmaceuticals, Daiichi Sankyo. Stavros Konstantinides reports having received consultancy and lecture honoraria from Bayer HealthCare, Boehringer Ingelheim, Actelion, Servier and BMS-Pfizer, payment for travel accommodation/meeting expenses from Bayer HealthCare and institutional grants from Boehringer Ingelheim, Bayer HealthCare, Daiichi Sankyo and Actelion.

• References

• 1 Konstantinides SV, Barco S, Lankeit M, Meyer G. Management of pulmonary embolism: an update. J Am Coll Cardiol 2016; 67 (08) 976-990
  CrossrefPubMedGoogle Scholar
• 2 Konstantinides SV, Torbicki A, Agnelli G. , et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35 (43) 3033-3069 , 3069a–3069k
  CrossrefPubMedGoogle Scholar
• 3 Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002; 121 (03) 877-905
  CrossrefPubMedGoogle Scholar
• 4 Aujesky D, Roy PM, Verschuren F. , et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011; 378 (9785): 41-48
  CrossrefPubMedGoogle Scholar
• 5 den Exter PL, Zondag W, Klok FA. , et al; Vesta Study Investigators*. Efficacy and safety of outpatient treatment based on the Hestia Clinical Decision Rule with or without N-terminal pro-brain natriuretic peptide testing in patients with acute pulmonary embolism. A randomized clinical trial. Am J Respir Crit Care Med 2016; 194 (08) 998-1006
  CrossrefPubMedGoogle Scholar
• 6 Zondag W, Kooiman J, Klok FA, Dekkers OM, Huisman MV. Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J 2013; 42 (01) 134-144
  CrossrefPubMedGoogle Scholar
• 7 Barco S, Lankeit M, Binder H. , et al. Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial. Thromb Haemost 2016; 116 (01) 191-197
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Becattini C, Agnelli G, Lankeit M. , et al. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur Respir J 2016; 48 (03) 780-786
  CrossrefPubMedGoogle Scholar
• 9 Becattini C, Casazza F, Forgione C. , et al. Acute pulmonary embolism: external validation of an integrated risk stratification model. Chest 2013; 144 (05) 1539-1545
  CrossrefPubMedGoogle Scholar
• 10 Meyer G, Vicaut E, Danays T. , et al; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370 (15) 1402-1411
  CrossrefPubMedGoogle Scholar
• 11 Schulman S, Kakkar AK, Goldhaber SZ. , et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772
  CrossrefPubMedGoogle Scholar
• 12 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
  CrossrefPubMedGoogle Scholar
• 13 Büller HR, Prins MH, Lensin AW. , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
  CrossrefPubMedGoogle Scholar
• 14 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
  CrossrefPubMedGoogle Scholar
• 15 Brekelmans MP, Ageno W, Beenen LF. , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol 2016; 3 (09) e437-e445
  PubMedGoogle Scholar
• 16 Klok FA, Meyer G, Konstantinides S. Management of intermediate-risk pulmonary embolism: uncertainties and challenges. Eur J Haematol 2015; 95 (06) 489-497
  CrossrefPubMedGoogle Scholar
• 17 Schulman S, Kearon C, Kakkar AK. , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
  CrossrefPubMedGoogle Scholar
• 18 Kucher N, Boekstegers P, Müller OJ. , et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129 (04) 479-486
  CrossrefPubMedGoogle Scholar
• 19 van der Meer RW, Pattynama PM, van Strijen MJ. , et al. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology 2005; 235 (03) 798-803
  CrossrefPubMedGoogle Scholar
• 20 van der Bijl N, Klok FA, Huisman MV. , et al. Measurement of right and left ventricular function by ECG-synchronized CT scanning in patients with acute pulmonary embolism: usefulness for predicting short-term outcome. Chest 2011; 140 (04) 1008-1015
  CrossrefPubMedGoogle Scholar
• 21 Trujillo-Santos J, den Exter PL, Gómez V. , et al. Computed tomography-assessed right ventricular dysfunction and risk stratification of patients with acute non-massive pulmonary embolism: systematic review and meta-analysis. J Thromb Haemost 2013; 11 (10) 1823-1832
  CrossrefPubMedGoogle Scholar
• 22 Klok FA, Van Der Bijl N, Eikenboom HC. , et al. Comparison of CT assessed right ventricular size and cardiac biomarkers for predicting short-term clinical outcome in normotensive patients suspected of having acute pulmonary embolism. J Thromb Haemost 2010; 8 (04) 853-856
  CrossrefPubMedGoogle Scholar
• 23 Lankeit M, Jiménez D, Kostrubiec M. , et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014; 43 (06) 1669-1677
  CrossrefPubMedGoogle Scholar
• 24 Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178 (04) 425-430
  CrossrefPubMedGoogle Scholar
• 25 Jiménez D, Aujesky D, Moores L. , et al; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170 (15) 1383-1389
  CrossrefPubMedGoogle Scholar
• 26 Hellenkamp K, Kaeberich A, Schwung J, Konstantinides S, Lankeit M. Risk stratification of normotensive pulmonary embolism based on the sPESI: does it work for all patients?. Int J Cardiol 2015; 197: 162-163
  CrossrefPubMedGoogle Scholar
• 27 Aujesky D, Stone RA, Kim S, Crick EJ, Fine MJ. Length of hospital stay and postdischarge mortality in patients with pulmonary embolism: a statewide perspective. Arch Intern Med 2008; 168 (07) 706-712
  CrossrefPubMedGoogle Scholar
• 28 Fanikos J, Rao A, Seger AC, Carter D, Piazza G, Goldhaber SZ. Hospital costs of acute pulmonary embolism. Am J Med 2013; 126 (02) 127-132
  CrossrefPubMedGoogle Scholar
• 29 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
  CrossrefPubMedGoogle Scholar
• 30 Klok FA, Hösel V, Clemens A. , et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 2016; 48 (05) 1369-1376
  CrossrefPubMedGoogle Scholar
• 31 Klok FA, Kooiman J, Huisman MV, Konstantinides S, Lankeit M. Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. Eur Respir J 2015; 45 (01) 201-210
  CrossrefPubMedGoogle Scholar
• 32 Klok FA, Barco S, Konstantinides SV. External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thromb Haemost 2017; 117 (06) 1164-1170
  Article in Thieme ConnectPubMedGoogle Scholar
• 33 Heidbuchel H, Verhamme P, Alings M. , et al; Advisors. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2016; ehw058
  CrossrefPubMedGoogle Scholar
• 34 Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. ; Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (03) 623-627
  CrossrefPubMedGoogle Scholar
• 35 Konstantinides SV, Vicaut E, Danays T. , et al. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. J Am Coll Cardiol 2017; 69 (12) 1536-1544
  PubMedGoogle Scholar